Related Experiment Video
Updated: Jan 29, 2026

11:36
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
22.6K
[(TREATMENT FOR CUTANEOUS LEISHMANIASIS: HISTORICAL ASPECTS)]
Meditsinskaia Parazitologiia I Parazitarnye Bolezni
|February 6, 2019
Summary
Traditional healers used varied treatments for cutaneous leishmaniasis with some success. Modern medicine still faces challenges due to a lack of specific drugs for this skin disease.
Area of Science:
- Dermatology
- Parasitology
- Medical History
Background:
- Cutaneous leishmaniasis treatment has evolved significantly over centuries.
- Traditional remedies for this parasitic skin infection showed variable efficacy.
- Understanding historical treatments provides context for current therapeutic challenges.
Observation:
- Ancient and traditional healing practices offered diverse regimens for cutaneous leishmaniasis.
- Some traditional treatments have demonstrated scientific rationale and are utilized today.
- A notable gap exists in the availability of etiotropic drugs within national healthcare systems.
Findings:
- Historical treatments for cutaneous leishmaniasis ranged in effectiveness.
- Scientific validation supports the use of certain traditional remedies in modern medicine.
- The current healthcare system lacks specific etiotropic drugs for cutaneous leishmaniasis.
Implications:
- Further research into validated traditional treatments could offer new therapeutic avenues.
- Addressing the drug deficit is crucial for effective cutaneous leishmaniasis management.
- Integrating historical knowledge with modern pharmacology may improve patient outcomes.
Related Concept Videos
Quantitative Aspects of Drug-Receptor Interaction
1.8K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.8K
Open Angle Glaucoma: Treatment
993
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
993
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
944
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
944
Anticholinesterase Agents: Poisoning and Treatment
1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K

